Skip to main content
. 2021 Dec 27;28(8):1680–1689. doi: 10.1158/1078-0432.CCR-21-3329

Figure 2.

Figure 2. Associations of gene signatures with response to pembrolizumab across tumor types. T-cell–inflamed GEP (A), mMDSC (B), angiogenesis (C), and stroma/EMT/TGFβ signatures (D). CR, complete response; EMT, epithelial-to-mesenchymal transition; GEP, gene expression profile; HNSCC, head and neck squamous cell carcinoma; mMDSC, monocytic myeloid-derived suppressor cells; NR, nonresponder; PR, partial response; R, responder; RCC, renal cell carcinoma; TGFβ, transforming growth factor β; TNBC, triple-negative breast cancer.

Associations of gene signatures with response to pembrolizumab across tumor types. T-cell–inflamed GEP (A), mMDSC (B), angiogenesis (C), and stroma/EMT/TGFβ signatures (D). CR, complete response; EMT, epithelial-to-mesenchymal transition; GEP, gene expression profile; HNSCC, head and neck squamous cell carcinoma; mMDSC, monocytic myeloid-derived suppressor cells; NR, nonresponder; PR, partial response; R, responder; RCC, renal cell carcinoma; TGFβ, transforming growth factor β; TNBC, triple-negative breast cancer.